AI Article Synopsis
Article Abstract
Purpose: Oral propranolol has been recently approved for infantile hemangiomas (IHs), but potential side effects stay a challenge. We sought to make an additional assessment on oral propranolol safety for this indication.
Materials And Methods: Prospective study included 108 infants consecutively treated for IHs at the University Children's Hospital Tirsova, Belgrade from January 2010 to December 2013. Propranolol was administered orally at a daily dose of 0.5 mg/kg and doubled every 48 hours in the absence of side effects until reaching the maximum dose of 2 mg/kg daily. Systolic and diastolic blood pressure and heart rate were measured every 48 hours with clinical observation. Heart rate was monitored by standard electrocardiogram (ECG) and 48-hour Holter ECG.
Results: Statistically significant, but asymptomatic decreases in systolic blood pressure and heart rate recorded by Holter ECG were observed during the first doubling of dose and then remained stable. Arrhythmias were not detected. Despite mild sleep disturbance observed in 31% of infants in the hospital milieu, Holter monitoring indicated circadian rhythm maintenance.
Conclusions: Oral propranolol for IHs does not remarkably affect heart rhythm including circadian variations throughout hospital initiation. Therefore, there is no necessity for Holter monitoring in additional safety assessment.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/09546634.2016.1277177 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy and safety of oral propranolol and topical timolol in the treatment of infantile hemangioma: a meta-analysis and systematic review.
Front Pharmacol
December 2024
Department of Pediatric Surgery, Guangzhou Women and Children's Medical Center, National Children's Medical Center for South Central Region, Guangzhou Medical University, Guangzhou, China.
Background: Propranolol, a nonselective β-blocker, is the first-line treatment for infantile hemangioma (IH). Topical timolol has recently been proposed as a novel IH treatment with fewer adverse effects. This study was conducted to compare the efficacy and safety of oral propranolol and topical timolol for treating IH.
View Article and Find Full Text PDFCombining treatments for migraine prophylaxis: the state-of-the-art.
J Headache Pain
December 2024
Department of Clinical and Molecular Medicine, Sapienza University, Rome, Italy.
Combination treatments for migraine prophylaxis present a promising approach to addressing the diverse and complex mechanisms underlying migraine. This review explores the potential of combining oral conventional prophylactics, onabotulinumtoxin A, monoclonal antibodies (mAbs) targeting the calcitonin gene-related peptide (CGRP) pathway, and small molecule CGRP receptor antagonists (gepants). Among the most promising strategies, dual CGRP inhibition through mAbs and gepants may enhance efficacy by targeting both the CGRP peptide and its receptor, while the combination of onabotulinumtoxin A with CGRP treatments offers synergistic pain relief.
View Article and Find Full Text PDFEfficacy of Propranolol and Pingyangmycin combination therapy in infantile hemangiomas: Correlation with VEGF levels.
J Stomatol Oral Maxillofac Surg
November 2024
Oral and Maxillofacial Surgery Department, Wuxi Stomatological Hospital 214000, Wuxi, PR China. Electronic address:
Article Synopsis
- The study focuses on evaluating the effectiveness of a treatment combining propranolol and pingyangmycin for infantile hemangiomas (IH), which are common vascular tumors in infants that can grow rapidly.
- Over 12 months, 120 children participated, with results showing significant reductions in both the Hemangioma Activity Score and serum levels of vascular endothelial growth factor (VEGF), indicating improved condition with treatment.
- The treatment was mostly well-tolerated, with mild and temporary side effects reported in 15% of patients, and there was a strong negative correlation between VEGF levels and hemangioma activity, suggesting the therapy's effectiveness relates to lowering VEGF.
Diagnosis and Treatment of Infantile Hemangioma from the Primary Care Paediatricians to the Specialist: A Narrative Review.
Children (Basel)
November 2024
Pediatric Unit, Department of Surgical Sciences, Destiny, Gynecology and Pediatrics, University of Verona, 37126 Verona, Italy.
Infantile haemangiomas (IHs) affect 3-10% of infants, 10% of whom need topical or systemic beta-blocker therapy. Propranolol is the first choice for IHs with a high risk of complications. Since more than half of IHs leave a permanent mark, to reduce outcomes, it is essential to start oral propranolol (2-3 mg/kg/day in 2 doses/day) within the 5th month of life (i.
View Article and Find Full Text PDFOur Experience in Treating Infantile Hemangioma: Prognostic Factors for Relapse After Propranolol Discontinuation.
Adv Ther
November 2024
Department of Dermatology, Rambam Health Care Campus, 8th Ha'aliya Hashnia, 3109601, Haifa, Israel.
Article Synopsis
- - Infantile hemangioma (IH) is a common benign tumor in infants that typically resolves on its own, but some cases require treatment with propranolol, which has a high success rate but may lead to rebound growth when stopped.
- - A study of 552 patients found that 12.6% experienced rebound growth after discontinuing propranolol; limb involvement predicted a lower likelihood of rebound growth, while younger age and a specific dose of 2 mg/kg/day improved treatment responses.
- - The research concluded that IHs on limbs displayed reduced rebound growth and better responses to propranolol, highlighting the importance of early treatment initiation and appropriate dosing for better outcomes.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!